Pharma BD Deal Intelligence
Sanofi acquired Provention Bio for $25 per share (approximately $2.9 billion total), gaining access to teplizumab (Tzield), the first FDA-approved therapy to delay the onset of type 1 diabetes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Provention Bio Inc. (this deal) | 2023 | $2.9B | 70 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2023 deals · Sanofi SA deals · Immunology deals